Keyphrases
ST-elevation Myocardial Infarction (STEMI)
100%
Primary Percutaneous Coronary Intervention
42%
Percutaneous Coronary Intervention
37%
Myocardial Infarction
27%
Fractional Flow Reserve
26%
Revascularization
22%
Acute Myocardial Infarction
20%
Infarct Size
20%
Clinical Outcomes
19%
Coronary Artery Disease
18%
Confidence Interval
18%
Hazard Ratio
17%
Complete Revascularization
12%
Randomized Clinical Trial
12%
Myocardial Infarction Patients
12%
Cardiac Magnetic Resonance
11%
Cardiac Magnetic Resonance Imaging (cMRI)
11%
Coronary Angiography
11%
Randomized Controlled Trial
11%
All-cause Mortality
11%
Invasive Coronary Angiography
9%
Small Vessel Disease
9%
Cardiogenic Shock
9%
Left Ventricular Function
9%
Ventricular Fibrillation
9%
Angiography
9%
Left Ventricular Ejection Fraction
9%
Final Infarct Size
8%
Culprit Lesion
8%
Bare Metal Stent
8%
Myocardial Salvage
7%
Stent Implantation
7%
Randomized Trial
7%
Adverse Cardiac Events
7%
Reperfusion
6%
Heart Failure
6%
Placebo
6%
Odds Ratio
6%
Denmark
6%
Infarct
6%
Glucagon-like
6%
Infarct-related Artery
6%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
6%
Drug-eluting Stent
6%
Stent
6%
Exenatide
5%
Acute Coronary Syndrome
5%
Ischemic Preconditioning
5%
Alirocumab
5%
High Risk
5%
Medicine and Dentistry
ST Segment Elevation Myocardial Infarction
69%
Percutaneous Coronary Intervention
42%
Myocardial Infarction
35%
Primary Percutaneous Coronary Intervention
30%
Coronary Artery Disease
26%
Fractional Flow Reserve
26%
Revascularization
25%
Infarction
24%
Coronary Angiography
19%
Cardiac Magnetic Resonance Imaging
19%
Hazard Ratio
14%
Acute Heart Infarction
14%
ST Elevation
11%
Randomized Controlled Trial
11%
Disease
11%
Acute Coronary Syndrome
10%
Percutaneous Aortic Valve Replacement
10%
Stenosis
10%
Angiography
9%
Randomized Clinical Trial
9%
Combination Therapy
8%
Artery
8%
Cardiogenic Shock
7%
Heart Failure
7%
Rapamycin
6%
Coronary Artery
6%
Heart Left Ventricle Ejection Fraction
6%
All Cause Mortality
6%
Bleeding
6%
Major Adverse Cardiac Event
6%
Ventricular Fibrillation
6%
Meta-Analysis
6%
Odds Ratio
6%
Symptom
6%
Placebo
6%
Drug-Eluting Stent
5%
Thorax Pain
5%
Intravascular Ultrasound
5%
Stenting
5%
Angina pectoris
5%
Aortic Valve Replacement
5%
Multidetector Computed Tomography
5%
Computer Assisted Tomography
5%
Glucagon Like Peptide 1
5%
Stent Thrombosis
5%
Alirocumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
ST Segment Elevation Myocardial Infarction
80%
Heart Infarction
39%
Infarction
35%
Acute Heart Infarction
18%
Randomized Clinical Trial
12%
Coronary Artery Disease
11%
All Cause Mortality
10%
Acute Coronary Syndrome
10%
Disease
10%
Placebo
9%
Bleeding
8%
Heart Failure
8%
Exendin 4
7%
Combination Therapy
6%
Heart Ventricle Fibrillation
6%
Cardiogenic Shock
6%
Ischemia
6%
Glucagon-Like Peptide-1
6%
Reperfusion Injury
6%
Stent Thrombosis
6%
Randomized Controlled Trial
5%
Umirolimus
5%
Rapamycin
5%
Heart Death
5%
Stenosis
5%
Clopidogrel
5%
Symptom
5%
Major Adverse Cardiac Event
5%
